Literature DB >> 21538282

Dissecting the genetic heterogeneity of gallbladder stone formation.

Marcin Krawczyk1, David Q-H Wang, Piero Portincasa, Frank Lammert.   

Abstract

Gallstone disease affects almost 20% of individuals in Westernized countries. As its incidence in the developing countries is rising considerably, currently, it is the second most common gastroenterological condition worldwide. Gallstone formation is driven by an interaction between genetic and environmental risk factors. Previous studies have demonstrated that the genetic background accounts for ~25% of the total disease risk. Linkage and case-control studies of candidate genes and recent genome-wide studies have identified multiple lithogenic genes, in particular the hepatocanalicular cholesterol transporter ABCG5/G8 and the bilirubin conjugating enzyme UGT1A1, as major genetic determinants of gallstones in humans. In this review, we summarize the recent findings related to the genetics of cholelithiasis, update the "inventory" of human lithogenic genes, and relate the genetic studies to the pathobiologic background of the disease. In closing, future applications of genetic testing for gallstone carriers and asymptomatic family members are addressed.
© 2011 Thieme Medical Publishers, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21538282     DOI: 10.1055/s-0031-1276645

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  21 in total

1.  Rafting for gallstones by slowing mass transit.

Authors:  Nicholas O Davidson
Journal:  J Physiol       Date:  2012-05-01       Impact factor: 5.182

2.  Dynamic liver test patterns do not predict bile duct stones.

Authors:  Chung Yao Yu; Nitzan Roth; Niraj Jani; Jaehoon Cho; Jacques Van Dam; Rick Selby; James Buxbaum
Journal:  Surg Endosc       Date:  2019-03-25       Impact factor: 4.584

Review 3.  The inflammatory inception of gallbladder cancer.

Authors:  Jaime A Espinoza; Carolina Bizama; Patricia García; Catterina Ferreccio; Milind Javle; Juan F Miquel; Jill Koshiol; Juan C Roa
Journal:  Biochim Biophys Acta       Date:  2016-03-12

Review 4.  Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.

Authors:  Helen H Wang; Piero Portincasa; Ornella de Bari; Kristina J Liu; Gabriella Garruti; Brent A Neuschwander-Tetri; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-02-19       Impact factor: 4.686

5.  Serum Plant Sterols Associate with Gallstone Disease Independent of Weight Loss and Non-Alcoholic Fatty Liver Disease.

Authors:  Pirjo Käkelä; Ville Männistö; Imre Ilves; Maija Vaittinen; Milla-Maria Tauriainen; Matti Eskelinen; Helena Gylling; Hannu Paajanen; Jussi Pihlajamäki
Journal:  Obes Surg       Date:  2017-05       Impact factor: 4.129

6.  Augmented cholesterol absorption and sarcolemmal sterol enrichment slow small intestinal transit in mice, contributing to cholesterol cholelithogenesis.

Authors:  Meimin Xie; Vijay R Kotecha; Jon David P Andrade; James G Fox; Martin C Carey
Journal:  J Physiol       Date:  2012-02-13       Impact factor: 5.182

Review 7.  Mouse models of gallstone disease.

Authors:  Tony Y Wang; Piero Portincasa; Min Liu; Patrick Tso; David Q-H Wang
Journal:  Curr Opin Gastroenterol       Date:  2018-03       Impact factor: 3.287

Review 8.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

Review 9.  Gallstones in patients with liver cirrhosis: incidence, etiology, clinical and therapeutical aspects.

Authors:  Monica Acalovschi
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Ezetimibe prevents the formation of oestrogen-induced cholesterol gallstones in mice.

Authors:  Ornella de Bari; Helen H Wang; Piero Portincasa; Chang-Nyol Paik; Min Liu; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2014-11-04       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.